AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

Group 1 - AstraZeneca will voluntarily delist its American Depositary Shares and certain guaranteed debt securities from Nasdaq, transitioning to a direct stock listing on the New York Stock Exchange (NYSE) [1] - The ordinary shares and affected debt securities are set to begin trading on the NYSE after market close on January 30, 2026, with trading expected to start on February 2, 2026 [1] - This move is part of a shareholder-approved plan to harmonize AstraZeneca's listing structure into a single global framework, allowing trading across the London Stock Exchange, Nasdaq Stockholm, and NYSE [2] Group 2 - Michel Demaré, Chair of AstraZeneca, stated that a global listing structure will enable the company to reach a broader mix of global investors, enhancing attractiveness for shareholders [3] - The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for AstraZeneca's Enhertu in combination with pertuzumab for treating unresectable or metastatic HER2-positive breast cancer [3][4] - The application is based on data from the DESTINY-Breast09 phase 3 trial, which showed a statistically significant improvement in progression-free survival compared to standard treatments [5] Group 3 - AstraZeneca shares were down 3.55% at $91.04 at the time of publication [6]